| Identification | Back Directory | [Name]
ECC5004 | [CAS]
3011682-51-9 | [Synonyms]
ECC5004
3-(1-(2-((S)-2-(3-cyclopropyl-4-fluorophenyl)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-4-methyl-
1,2,4-Oxadiazol-5(2H)-one, 3-[1-[2-[[(4S)-2-(3-cyclopropyl-4-fluorophenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-7-[(4R)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-3-indolizinyl]cyclopropyl]- | [Molecular Formula]
C48H46F2N10O5 | [MOL File]
3011682-51-9.mol | [Molecular Weight]
880.94 |
| Hazard Information | Back Directory | [Uses]
GLP-1 receptor agonist 14 (compound 73) is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 14 plays an important role in diabetes or other metabolic disorders[1]. | [References]
[1] Ren Zaifang, et al. Preparation of tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds as GLP-1 receptor modulators and methods of using same. World Intellectual Property Organization, WO2022017338 A1 2022-01-27 |
|
| Company Name: |
RuiKeXin
|
| Tel: |
19938953786 |
| Website: |
ahreaction.com/ |
|